SCHEMBL21484670

SCHEMBL21484670

CC(C)(C)c1cc(/C=C(\C#N)C(=O)Nc2nc(-c3ccccn3)cs2)cc(C(C)(C)C)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 2/20 0.61
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ADORA3 P0DMS8 5/20 0.47
KDM4A O75164 2/20 0.47
KDM4B O94953 2/20 0.47
KDM5B Q9UGL1 2/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
HSP90AA1 P07900 2/20 0.47
EGFR P00533 1/20 0.46
MAPT P10636 4/20 0.46
ALDH1A1 P00352 4/20 0.46
RAB9A P51151 3/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 1/20 0.45
KDM4E B2RXH2 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21505934 0.88 ADORA3 (0.50) MRE11MEN1KMT2AADORA3KDM4A
SCHEMBL21484735 0.88 LMNA (0.48) MRE11MEN1KMT2AADORA3EGFR
SCHEMBL21484913 0.86 ADORA3 (0.52) MRE11KMT2AADORA3KDM4AKDM4B
SCHEMBL21505933 0.86 SLC2A1 (0.53) MRE11MEN1KMT2AADORA3KDM4A
SCHEMBL21484751 0.84 MRE11 (0.51) MRE11MEN1KMT2AEGFRMAPT
SCHEMBL21484598 0.83 MRE11 (0.57) MRE11MEN1KMT2AADORA3KDM4A
SCHEMBL21484858 0.83 MRE11 (0.50) MRE11MEN1KMT2AEGFRMAPT
SCHEMBL21484780 0.79 MRE11 (0.51) MRE11MEN1KMT2AEGFRMAPT
SCHEMBL21484777 0.79 MRE11 (0.51) MRE11MEN1KMT2AL3MBTL1EGFR
SCHEMBL21484887 0.77 LMNA (0.47) MRE11MEN1KMT2AADORA3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 MRE11 86/4885MEN1 1573/4885KMT2A 1049/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 MRE11 86/4885MEN1 1573/4885KMT2A 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.